3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1/2
1
Status
Completed
7
Recruiting
3
Active not recruiting
3
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Posterior Fossa Ependymal Tumor
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
125
pembrolizumab
123
Magnetic Resonance Spectroscopy
108
Carboplatin
89
Cyclophosphamide
80
Biopsy
69
Cisplatin
67
Paclitaxel
61
Bevacizumab
56
Gemcitabine
54
Nivolumab
49
fludarabine
48
Dexamethasone
41
Rituximab
39
Pemetrexed
39
Fluorouracil
39
Radiotherapy
37
Doxorubicin
37
atezolizumab
36
Docetaxel
36
Leucovorin
35
Oxaliplatin
32
Capecitabine
32
venetoclax
31
Temozolomide
29
Prednisone
29
durvalumab
27
Standard of Care
27
Radiation
27
Letrozole
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Metformin
×
30 days
×
Clear all
NCT07226453
2026-06-05
PNOC041
University of California, San Francisco
Phase 2
Recruiting
30 enrolled
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT05515978
2026-06-02
PragMet
University of Colorado, Denver
Phase EARLY_PHASE1
Recruiting
100 enrolled